Table 4 Subgroup analysis
Cardiovascular Diseases | Cerebrovascular Diseases | Heart Dysfunction | Composite outcome | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Patients with outcome | HR (95% CI) | Patients with outcome | HR (95% CI) | Patients with outcome | HR (95% CI) | Patients with outcome | HR (95% CI) | |||||
HPV vaccine | Non-HPV vaccine | HPV vaccine | Non-HPV vaccine | HPV vaccine | Non-HPV vaccine | HPV vaccine | Non-HPV vaccine | |||||
Sex | ||||||||||||
Female (n = 39,578) | 1260 | 1595 | 0.807 (0.749, 0.868) | 90 | 148 | 0.625 (0.481, 0.812) | 157 | 238 | 0.679 (0.555, 0.831) | 1323 | 1706 | 0.791 (0.736, 0.85) |
Male (n = 15,067) | 503 | 521 | 0.948 (0.839, 1.072) | 23 | 44 | 0.512 (0.309, 0.848) | 105 | 122 | 0.847 (0.653, 1.1) | 517 | 555 | 0.914 (0.811, 1.03) |
Age | ||||||||||||
20–30 (n = 49,563) | 1639 | 1759 | 0.934 (0.873, 0.999) | 81 | 134 | 0.609 (0.462, 0.802) | 211 | 247 | 0.859 (0.715, 1.032) | 1699 | 1859 | 0.916 (0.857, 0.978) |
30–40 (n = 13,595) | 500 | 685 | 0.767 (0.684, 0.861) | 50 | 67 | 0.802 (0.556, 1.158) | 82 | 101 | 0.864 (0.646, 1.157) | 534 | 732 | 0.767 (0.686, 0.858) |
Race | ||||||||||||
Black or African American (n = 8496) | 291 | 335 | 0.855 (0.731, 1.001) | 24 | 49 | 0.485 (0.298, 0.79) | 61 | 81 | 0.745 (0.535, 1.039) | 308 | 368 | 0.823 (0.708, 0.958) |
White (n = 35,692) | 1318 | 1511 | 0.886 (0.823, 0.954) | 66 | 113 | 0.599 (0.442, 0.811) | 169 | 209 | 0.826 (0.674, 1.011) | 1365 | 1599 | 0.867 (0.807, 0.932) |
Asian (n = 4498) | 82 | 107 | 0.834 (0.625, 1.112) | 12 | 16 | 0.822 (0.389, 1.739) | 10* | 14 | 0.549 (0.221, 1.36) | 88 | 120 | 0.798 (0.606, 1.051) |
Other race (n = 3504) | 111 | 121 | 0.895 (0.691, 1.157) | 10* | 10* | 0.492 (0.148, 1.633) | 16 | 19 | 0.826 (0.425, 1.606) | 114 | 125 | 0.89 (0.69, 1.147) |